Takeda Pharmaceutical Company Limited (4502) Q3 Financial Summary for Fiscal Year Ending March 2026

Performance Overview

For Q3 of the fiscal year ending March 2026, consolidated revenue was 3,411.2 billion yen (3.3% YoY decrease), mainly impacted by revenue decline due to generic penetration of the ADHD treatment VYVANSE in the Neuroscience segment. Meanwhile, the Gastrointestinal diseases, Plasma-Derived therapies, Oncology, and Vaccines segments posted revenue growth. Operating income increased slightly to 422.4 billion yen (1.2% YoY increase), with quarterly profit rising to 216.3 billion yen (2.4% YoY increase). Core operating income was 971.6 billion yen (3.4% YoY decrease), supported by cost reductions from efficiency programs. Regionally, revenue grew in Japan, Europe & Canada, and China, but declined in the United States.

Revision and Outlook of Full-Year Earnings Guidance

For the full fiscal year ending March 2026, consolidated earnings guidance has been revised upward to revenue of 4,530 billion yen (0.7% increase from previous forecast), operating income of 410 billion yen (2.5% increase), and net income of 154 billion yen (0.7% increase). The major driver of revenue growth is the forecasted weaker yen exchange rate, expected to partially offset the revenue decline from increased generic competition for VYVANSE. Core operating income guidance was also raised to 1,150 billion yen. While efficiency program cost savings are expected to continue, increased amortization expenses for intangible assets are anticipated to partially offset earnings growth.